Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Galmed Pharmaceuticals Ltd News

    0,361 $ -9,52% -0,038 $
    In : 0,3381 € | 20:17:57 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1XFUX
    ISIN: IL0011313900
    US-Symbol: GLMD
    Typ: Aktie

    Galmed Pharmaceuticals Ltd News

    04.04.24 - PR Newswire
    Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
    Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 PR Newswire
    15.03.24 - PR Newswire
    Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
    Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis PR Newswire
    20.11.23 - PR Newswire
    Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
    Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study PR Newswire
    26.09.23 - PR Newswire
    Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
    Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis PR Newswire
    22.09.23 - PR Newswire
    Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
    Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire
    14.07.23 - PR Newswire
    Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
    Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering PR Newswire
    13.07.23 - PR Newswire
    Thinking about buying stock in Healthcare Triangle, Galmed Pharmaceuticals, Express, Kartoon Studios, or Aeroports de Paris?
    Thinking about buying stock in Healthcare Triangle, Galmed Pharmaceuticals, Express, Kartoon Studios, or Aeroports de Paris? PR Newswire
    10.07.23 - PR Newswire
    Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
    Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC PR Newswire
    01.06.23 - PR Newswire
    Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
    Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments PR Newswire
    09.05.23 - PR Newswire
    Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)
    Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC) PR Newswire
    29.03.23 - PR Newswire
    Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
    Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 PR Newswire
    08.02.23 - PR Newswire
    Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
    Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt PR Newswire
    14.12.22 - PR Newswire
    Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
    Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement PR Newswire
    04.08.22 - PR Newswire
    Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
    Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results PR Newswire
    07.07.22 - PR Newswire
    Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
    Galmed Reports Significant Anti-​Fibrotic Effects of Aramchol in a Lung Fibrosis Model PR Newswire
    31.10.19 - PR Newswire
    Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019
    Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019 PR Newswire
    09.04.19 - PR Newswire
    Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3
    Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3 PR Newswire
    09.05.18 - PR Newswire
    Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results
    Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results - Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - PR ...
    27.03.18 - PR Newswire
    Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL
    Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL PR Newswire
    07.11.17 - PR Newswire
    Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference
    Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference PR Newswire

    Newssuche

    Videos

    newspaper
    09:15 Uhr -8,87%
    Technical Trading: Sojabohnen Long bis Juli
    Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »